CClinicalTrials.gg
Sign In
CompletedNCT07622966Updated Jun 3, 2026

Effect of Osteopathic Manipulation on Circulating Immune Markers

An interventional study of Osteopathic Manipulative Treatment (OMT) and Sham Comparator in Healthy Adult Participants and Osteopathic Manipulative Treatment (OMT), sponsored by Edward Via Virginia College of Osteopathic Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Edward Via Virginia College of Osteopathic Medicine · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jan 2025, registered May 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if osteopathic manipulative treatment (OMT) changes levels of immune markers in healthy volunteers. The main questions it aims to answer are:

Does OMT change numbers of white blood cells or antibodies? Does OMT change levels of cytokines?

Researchers will compare volunteers treated with OMT to volunteers undergoing sham treatment to see if OMT changes levels of immune markers.

Participants will:

  • complete a survey about their medical history to determine if they are healthy enough for OMT
  • have blood drawn
  • undergo either sham treatment or OMT
  • have blood drawn 30 minutes after treatment
02

Conditions studied

  • Healthy Adult Participants
  • Osteopathic Manipulative Treatment (OMT)
03

In context

Lead sponsor

Edward Via Virginia College of Osteopathic Medicine is the lead sponsor of 24 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • subjects are healthy; have independently read, understood, and without coercion signed the consent form; agree to allow for samples to be taken; agree to fill out all the documentation and surveys; and identifies as any race(s), ethnicity(ies), and/or gender(s)

Exclusion criteria

Exclusion Criteria:

  • subjects present at initial visit with a fever greater than 100.5 °F; have participated in a clinical trial within the last 6 months; work night shifts; who are immunocompromised including: HIV+, have had cancers, or are pregnant or nursing; have current bone fractures of the head and neck; history of osteoporosis, acute hepatitis, deep vein thrombosis, pulmonary embolism, trauma to the liver or spleen, surgery in the past 6 months or necrotizing fasciitis. Other relative contraindications to receiving OMT include doderate to severe cardiac conditions, moderate to severe congestive heart failure, infectious mononucleosis, chronic abscesses or osteomyelitis, coagulopathies or patients on anticoagulants, COPD, and acute indurated lymph node
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Osteopathic Manipulative Treatment (OMT)

    Other: Osteopathic Manipulative Treatment (OMT)

  • Sham comparator
    Sham Treatment

    Other: Sham Comparator

Interventions

  • OtherOsteopathic Manipulative Treatment (OMT)

    Lymphatic Pump Techniques

  • OtherSham Comparator

    Light touch

06

What researchers measure

Primary outcomes

  1. Changes in Circulating Immune Markers

    Time frame: within 30 minutes of treatment

07

Study locations

1 site
  • Edward Via College of Osteopathic Medicine
    Monroe, Louisiana 71203, United States
08

References and documents

Individual participant data

Plan to share: No — IPD sharing was not part of patients informed consent

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622966
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Collaborators
American Osteopathic Association
Responsible party
Rebekah Morrow (Discipline Chair for Immunology and Microbiology, Edward Via Virginia College of Osteopathic Medicine) — Principal investigator
First posted
Jun 3, 2026
Start date
Jan 10, 2025
Primary completion
Jun 17, 2025
Completion
Jun 17, 2025
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Edward Via Virginia College of Osteopathic Medicine

Start the discussion